Harald Ittrich MD, Presenter: Nothing to Disclose

Nina Raabe MD, Abstract Co-Author: Nothing to Disclose

Kersten Peldschus MD, Abstract Co-Author: Nothing to Disclose

Michael Gerhard Kaul, Abstract Co-Author: Nothing to Disclose

Gerhard B. Adam MD, Abstract Co-Author: Nothing to Disclose

1. SPIO can be used for diagnostic MRI and therapy and may qualify for MPI. 2. Monodisperse SPIO improve physicochemistry and pharmacodynamics. 3. SPIO in targeted probes enable in in vitro diagnostic imaging (μNMR).

SPIO can be used to image anatomical, cellular and molecular changes. Clinical applications range from MRA to the imaging of tumors, lymph nodes, CNS, atherosclerotic plaque and thrombosis. New experimental approaches describe undirected SPIO trapping in inflammation and tumors and directed accumulation of SPIO ligands in/on tumor and apoptotic cells, infarction, inflammation and degeneration in cardiovascular and neurological diseases, in atherosclerosis or thrombi. Stem cell labeling allows imaging of cell therapies or transplant rejections. SPIO coupling to ligands, radio- and/or chemotherapeutics, embedding in carrier systems or activatable smart sensor probes enable molecular tumor therapies or the imaging of metabolic and enzymatic processes. Monodisperse SPIO may improve SPIO-based MRI in the future and as targeted probes in diagnostic magnetic resonance. Chip-based μNMR may improve in vitro analysis methods for biomarkers, pathogens and tumor cells. Magnetic particle imaging (MPI) offers new applications for SPIO in cardiovascular, oncological, cellular and molecular diagnostics and therapy.

http://abstract.rsna.org/uploads/2014/14015007/14015007_6caq.pdf

Ittrich, H, Raabe, N, Peldschus, K, Kaul, M, Adam, G, Superparamagnetic Iron Oxide Nanoparticles in Biomedicine: Applications and Developments in Diagnostics and Therapy.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14015007.html